S 247567
Alternative Names: S247567Latest Information Update: 06 Feb 2026
At a glance
- Originator Servier
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 31 Jan 2026 Preclinical trials in Haematological malignancies in France (unspecified route) (Servier pipeline, January 2026)